Consumer Macro Strategy - The overall performance of the discretionary consumption sector is flat as the year-end approaches, but high-end consumption, including duty-free shopping in islands, is expected to gradually stabilize overall consumption [2][10] - The implementation plan released on November 26 aims to enhance the adaptability of supply and demand for consumer goods, with a goal to optimize the supply structure by 2027, creating three trillion-yuan consumption fields and ten hundred-billion-yuan consumption hotspots [2][10] - By 2030, a high-quality development pattern of mutual promotion between supply and consumption is expected to be established, with consumption steadily contributing to economic growth [2][10] New Consumption Manufacturing - The pet economy continues to thrive, with companies like Guobao Pet investing in high-end pet food factories in New Zealand, enhancing competitiveness in international markets [23][24] - The AI and 3D printing sector is rapidly evolving, with significant advancements expected in consumer-grade 3D printing by 2026, driven by companies like Huina Technology and Snapmaker [25][26] - The integration of AI with 3D printing is being promoted in educational settings, expanding the supply space for the industry [25] Light Industry Manufacturing - The home appliance sector is facing weak domestic demand, but there are opportunities for companies with overseas production capabilities and brand advantages as demand recovers [26][27] - The new tobacco sector is experiencing growth, particularly in e-cigarette exports to the U.S., which saw a significant increase in October [27][28] - The packaging industry is showing signs of profitability improvement despite a slight decline in revenue, driven by leading companies capturing market share from smaller firms [28] Textile and Apparel - The apparel sector is experiencing fluctuations in consumer demand, with a focus on companies that can demonstrate unique advantages in the market [30][31] - The export market remains under pressure due to trade tensions, but leading textile manufacturers are expected to present investment opportunities as they maintain strong positions in the industry [31] Beauty and Personal Care - The beauty sector shows positive fundamentals, with a 9.6% year-on-year increase in retail sales for cosmetics in October, although valuations have been affected by the new consumption sector [32][33] - The medical beauty segment is expanding, with new products gaining regulatory approval, indicating growth potential in the market [33] Home Appliances - Focus on two directions: resilient white goods leaders with strong cash flow and black goods leaders benefiting from optimized domestic sales and stable costs [34][35] - The white goods sector is facing pressure in domestic sales, while black goods are seeing improvements in average prices and export recovery [36][37]

现代健康科技(00919)发布截至2025年9月30日止6个月中期业绩，该集团取得收益2.23亿港元，同比减少 0.7%;公司权益股东应占溢利654.4万港元，去年同期亏损1630.2万港元;每股基本盈利0.72港仙。 公告称，集团的收益主要源自美容、面部护理和纤体服务。集团取得美容及面部护理服务的收益较去年 同期减少5.2%。于回顾期间，纤体服务的收益较2024年同期减少约0.3%。同时，于回顾期间，集团的 水疗浸浴及按摩收益增加28.6%。产品收益较去年同期增加30.0%。 ...

Core Viewpoint - The retail industry is experiencing increased market volatility as of the end of 2025, with a focus on capturing new consumption trends and expectations for a reversal of traditional consumption challenges [1] 2025 Review - In the first nine months of 2025, the total retail sales reached 36,587.7 billion yuan, reflecting a year-on-year growth of 4.5%, with retail sales of consumer goods excluding automobiles growing by 4.9% [2] - By category, cosmetics sales grew by 3.9%, while gold and jewelry sales surged by 11.5% due to a low base last year and rising gold prices [2] - Cross-border e-commerce imports and exports reached approximately 2,060 billion yuan, marking a 6.4% increase, demonstrating resilience despite external impacts such as tariffs [2] - The consumption landscape shows structural highlights in sectors like pets, trendy toys, personal care, and jewelry, driven by insights into new consumer demands and product innovation [2] - The new consumption industry trends and expectations for a reversal in traditional consumption challenges are identified as the two main themes, with a positive market performance at the beginning of the year followed by a cooling trend later on [2] 2026 Outlook - New markets will be explored domestically, including customer return during offline channel adjustments and new dividends from innovative business models like instant retail, while overseas expansion remains crucial for Chinese brands [3] - New demands will focus on insights into emerging consumer preferences, emphasizing emotional and practical value in products, and exploring innovation through IP+ and AI+ [3] - A platform-based approach is necessary due to intensified competition, requiring companies to create mechanisms for continuous growth through both internal and external opportunities [3] Investment Recommendations - For beauty and personal care, focus on leading companies with room for product innovation and those with platform capabilities for iterative growth, such as Shangmei Co., Proya, and others [4] - In the gold and jewelry sector, companies with differentiated designs and expansion potential are expected to benefit, including Chao Hong Ji and Chow Tai Fook [4] - For cross-border e-commerce, leading firms expanding in target markets and new categories will see sustained fundamental catalysts, such as Small Commodity City and Anker Innovations [4] - In offline retail, companies showing initial operational improvements should be monitored, including Jiajiayue and Miniso [4]

Core Insights - The report maintains an "outperform" rating for the retail sector, highlighting the potential for recovery in consumer demand and the importance of adapting to new market conditions [1][4][10] 2025 Industry Review - In the first three quarters of 2025, China's retail sales reached 365,877 billion yuan, growing by 4.5% year-on-year, with non-automotive retail sales increasing by 4.9% [2][10] - The cosmetics sector saw a stable growth of 3.9%, while gold and jewelry sales surged by 11.5% due to low base effects and rising gold prices [2][26] - Cross-border e-commerce imports and exports amounted to approximately 2.06 trillion yuan, reflecting a growth of 6.4% despite external pressures [2][33] 2026 Outlook - New markets will be explored, including offline channel adjustments and innovations in instant retail, alongside continued overseas expansion opportunities [3][61] - New consumer demands will focus on emotional and practical value, leveraging AI and IP for product innovation [3][66] - A platform-based approach is necessary to ensure sustainable growth amid intensifying competition and shorter product life cycles [3][66] Investment Recommendations - The report suggests focusing on leading companies in beauty care, gold and jewelry, cross-border e-commerce, and offline retail, with specific recommendations for companies like Up Beauty, Chow Tai Fook, and Yonghui Superstores [4][34] - The beauty care sector is expected to benefit from product innovation and platform capabilities, while gold and jewelry companies are advised to capitalize on differentiated designs [4][45] - Cross-border e-commerce firms are projected to thrive as external tariff impacts diminish, with recommendations for companies like Anker Innovations and Focus Technology [4][54] Consumer Behavior Trends - The report notes a structural shift in consumer preferences, with a growing emphasis on emotional value and product differentiation, particularly among younger demographics [3][78] - Instant retail is identified as a significant growth area, with the market expected to exceed 2 trillion yuan by 2030 [3][80] Cross-Border E-commerce Insights - Cross-border e-commerce continues to show resilience, with exports to the EU growing by 8.4% while exports to the US declined by 17% due to tariff impacts [33][87] - Successful brands in overseas markets are those that effectively combine global branding with localized operational strategies [87]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4494.42 points, up 0.15%, with a trading volume of 7.52 billion yuan and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Medical Pulse leading the gainers at 3.65% and Health Road leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight, latest price 196.30 yuan, market cap 238 billion yuan, up 1.50%) [1] - Yier Eye Hospital (11.62% weight, latest price 11.40 yuan, market cap 106.31 billion yuan, down 0.26%) [1] - Lejin Medical (4.85% weight, latest price 15.87 yuan, market cap 29.26 billion yuan, up 0.13%) [1] - Aimeike (4.80% weight, latest price 146.26 yuan, market cap 44.26 billion yuan, up 0.83%) [1] - Yuyue Medical (4.66% weight, latest price 35.70 yuan, market cap 35.79 billion yuan, down 0.67%) [1] - Yingke Medical (3.64% weight, latest price 41.53 yuan, market cap 27.21 billion yuan, up 1.94%) [1] - Furuide (3.59% weight, latest price 67.08 yuan, market cap 17.78 billion yuan, up 1.36%) [1] - Meinian Health (3.58% weight, latest price 5.28 yuan, market cap 20.67 billion yuan, down 1.68%) [1] - Sinopharm (3.35% weight, latest price 18.42 yuan, market cap 57.48 billion yuan, down 0.69%) [1] - Ping An Good Doctor (2.63% weight, latest price 13.66 yuan, market cap 29.52 billion yuan, down 1.83%) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 58.83 million yuan, while retail investors saw a net inflow of 78.07 million yuan [1] - Specific stock capital flows include: - Aimeike: Main fund net inflow of 46.99 million yuan, retail net outflow of 30.07 million yuan [2] - Mindray Medical: Main fund net inflow of 33.08 million yuan, retail net outflow of 17.11 million yuan [2] - Furuide: Main fund net inflow of 13.68 million yuan, retail net outflow of 19.08 million yuan [2] Recent Adjustments - The Shenzhen-Hong Kong Medical Index has undergone adjustments in the last 10 days, with one new stock added [2]

Core Points - The Biotech Index (970038) closed at 2134.66 points, down 0.06%, with a trading volume of 13.045 billion yuan and a turnover rate of 0.95% [1] - Among the index constituents, 22 stocks rose while 27 fell, with Hualan Vaccine leading the gainers at 2.57% and Jingxin Pharmaceutical leading the decliners at 5.97% [1] Index Constituents Summary - The top ten constituents of the Biotech Index include: - Mindray Medical (12.58% weight, latest price 196.30 yuan, market cap 238 billion yuan) [1] - Changchun High-tech (4.87% weight, latest price 99.66 yuan, market cap 40.655 billion yuan) [1] - Shimi Aoshi (4.74% weight, latest price 6.60 yuan, market cap 4.3811 billion yuan) [1] - Kanglong Chemical (4.55% weight, latest price 28.87 yuan, market cap 51.337 billion yuan) [1] - Tigermed (4.54% weight, latest price 51.20 yuan, market cap 44.085 billion yuan) [1] - Deep Technology (4.16% weight, latest price 23.42 yuan, market cap 36.809 billion yuan) [1] - Muyuan Food (3.62% weight, latest price 49.90 yuan, market cap 272.592 billion yuan) [1] - Lepu Medical (3.19% weight, latest price 15.87 yuan, market cap 29.255 billion yuan) [1] - Aimeike (3.16% weight, latest price 146.26 yuan, market cap 44.257 billion yuan) [1] - Seeyou Medical (3.07% weight, latest price 35.70 yuan, market cap 35.788 billion yuan) [1] Capital Flow Analysis - The Biotech Index constituents experienced a net outflow of 84.2481 million yuan from institutional investors, while retail investors saw a net inflow of 67.1618 million yuan [1] - Notable capital flows include: - Muyuan Food: 104 million yuan net inflow from institutional investors, but net outflows from retail and speculative investors [2] - Aimeike: 46.9918 million yuan net inflow from institutional investors, with outflows from retail and speculative investors [2] - Mindray Medical: 33.0761 million yuan net inflow from institutional investors, with outflows from retail and speculative investors [2]

| 建筑材料 | | | | 国统股份 | | | --- | --- | --- | --- | --- | --- | | 传媒 | -0.39 | 436.88 | -24.40 | 欢瑞世纪 | -9.95 | | 商贸零售 | -0.46 | 180.58 | 22.34 | 凯淳股份 | -11.20 | | 综合 | -0.96 | 35.25 | 5.30 | 三木集团 | -4.36 | 证券时报·数据宝统计，截至上午收盘，今日沪指涨0.49%，A股成交量684.66亿股，成交金额10970.18 亿元，比上一个交易日减少4.06%。个股方面，3338只个股上涨，其中涨停53只，1884只个股下跌，其 中跌停9只。从申万行业来看，电子、美容护理、轻工制造等涨幅最大，涨幅分别为1.75%、1.26%、 1.00%；综合、商贸零售、传媒等跌幅最大，跌幅分别为0.96%、0.46%、0.39%。（数据宝） （文章来源：证券时报网） 今日各行业表现（截至上午收盘） | 申万行业 | 行业涨跌（%） | 成交额（亿元） | 比上日（%） | 领涨（跌）股 | 涨跌幅（%） | | --- | --- ...

ABSTRACT 摘 要 择时展望： （ 1 ）从信用通胀的宏观角度，估值、风险溢价、情绪等微观视角观察， 2026 年 A 股总 体有望继续迎来慢牛回升。（ 2 ）本轮杠杆率上行主要为债务稳定，产出走弱，不同于以往，在见到 产出走强之前，宽松周期预期将大概率维持，自上而下看，权益市场上行弹性更大。（ 3 ）风险溢价 目前处于均衡区域，创业板指风格估值相对历史总体处于中位数水平。（ 4 ）情绪视角看，股价处于 200 日均线以上的个股占总体的比例，反应市场高低热度，该指标目前处于均衡区域。（ 5 ）使用卷 积神经网络对图表化的价量数据与未来价格进行建模，最新配置主题关注能源、高股息等。 风格与行业配置展望： （ 1 ）积极关注宏观政策环境变化，挖掘利好的方向及板块。我们预计随着宏 观经济环境的不断向好，明年市场宏观环境上可能迎来通胀改善上行趋势。 PPI 筑底上行趋势阶段， 小市值成长风格表现明显占优。小票及成长、消费等板块表现较为占优。按照风格指数表现上看，中信 消费及成长风格指数表现最佳，行业的表现中，靠前的行业分别为社会服务、美容护理、电力设备、医 药生物、电子等。（ 2 ）挖掘目前相对及绝对估值较低且 ...

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4375.4 points on November 25, with a 0.52% increase and a trading volume of 8.459 billion HKD, indicating a positive market sentiment in the healthcare sector [1]. Group 1: Index Performance - The index had 40 stocks rising and 16 stocks falling on the day, with Ping An Good Doctor leading the gainers at a 4.27% increase, while Ruimaite led the decliners with a 1.98% drop [1]. - The index's turnover rate was 0.84%, reflecting moderate trading activity [1]. Group 2: Component Stocks Details - The top ten component stocks of the index include: - Mindray Medical (14.56% weight, 193.88 HKD, 0.46% increase, market cap 235.068 billion HKD) [1] - Yeye Eye Hospital (11.62% weight, 11.59 HKD, 0.35% increase, market cap 108.081 billion HKD) [1] - Lejin Medical (4.85% weight, 15.80 HKD, 0.45% increase, market cap 29.126 billion HKD) [1] - Aimeike (4.80% weight, 145.54 HKD, -0.31% decrease, market cap 44.039 billion HKD) [1] - Yuyue Medical (4.66% weight, 35.67 HKD, -0.14% decrease, market cap 35.758 billion HKD) [1] - Yingke Medical (3.64% weight, 40.26 HKD, 0.20% increase, market cap 26.362 billion HKD) [1] - Furuishi (3.59% weight, 65.75 HKD, -1.50% decrease, market cap 17.422 billion HKD) [1] - Meinian Health (3.58% weight, 5.42 HKD, 0.74% increase, market cap 21.215 billion HKD) [1] - Sinopharm (3.35% weight, 18.55 HKD, 0.49% increase, market cap 57.888 billion HKD) [1] - Ping An Good Doctor (2.63% weight, 13.33 HKD, 4.27% increase, market cap 28.822 billion HKD) [1]. Group 3: Capital Flow - The net outflow of main funds from the index's component stocks totaled 251 million HKD, while retail investors saw a net inflow of 199 million HKD [1]. - The detailed capital flow indicates that while main funds were withdrawing, retail investors were actively buying into the market [2]. Group 4: Recent Adjustments - In the last 10 days, the index underwent adjustments, adding one new stock, Jianfa Zhixin, which is in the medical biology sector with a market cap of 13.886 billion HKD [3].

| 生物经济指数 十大成份股 | | --- | | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 12.58% | 193.88 | 0.46% | 2350.68 | 医药生物 | | sz000661 | 长春高新 | 4.87% | 99.46 | 0.10% | 405.73 | 医药生物 | | sz002252 | 十肖史上 | 4.74% | 6.62 | -0.15% | 439.43 | 医药生物 | | sz300759 | 康龙化成 | 4.55% | 29.07 | 0.24% S | 516.92 | 医药生物 | | sz300347 | 泰格医药 | 4.54% | 50.86 | 0.32% | 437.92 | 医药生物 | | sz000021 | 深科技 | 4.16% | 23.38 | 1.65% | 367.46 | 电子 | | sz002714 | 牧原股份 | 3.62% | 49. ...